Subacute L-DOPA in mice: biochemical and behavioural effects
- PMID: 6771801
- DOI: 10.1007/BF00426654
Subacute L-DOPA in mice: biochemical and behavioural effects
Abstract
Mice, pretreated orally with L-DOPA (200 mg/kg) plus benserazide (50 mg/kg) (L-DOPA-B) responded when challenged 24 h later with the same drug combination, with significantly greater locomotor stimulation than animals pretreated with the vehicle. The enhanced response was not due to an intrinsic effect of benserazide. Nor was it dependent on a change in central dopamine (DA) receptor sensitivity, because the two pretreatment groups (L-DOPA-A and vehicle) did not differ in their locomotor response to a range of apomorphine doses (300--3,000 micrograms/kg, IP). The enhanced response was, however, due to DA receptor stimulation because it was antagonised by premedication of the mice with haloperidol or pimozide. Moreover, the enhanced response to L-DOPA-B chf L-DOPA alone (without benserazide) (1,200 mg/kg, orally). Animals which had been pretreated with L-DOPA-B had significantly higher brain levels of L-DOPA and DA after a subsequent challenge dose of L-DOPA-B administered 24 h later. Thus the enhanced response to L-DOPA-B observed in the present experiment appears to be dependent on some mechanism which produces higher concentrations of L-DOPA (and consequently DA) in the brain.
Similar articles
-
Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.Naunyn Schmiedebergs Arch Pharmacol. 1983 Dec;324(4):271-4. doi: 10.1007/BF00502622. Naunyn Schmiedebergs Arch Pharmacol. 1983. PMID: 6686648
-
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.J Neural Transm. 1981;50(2-4):209-24. doi: 10.1007/BF01249143. J Neural Transm. 1981. PMID: 6787171
-
Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.Neurosci Res. 2010 Sep;68(1):44-50. doi: 10.1016/j.neures.2010.06.003. Epub 2010 Jun 11. Neurosci Res. 2010. PMID: 20542064
-
The pharmacology of Parkinson's disease: basic aspects and recent advances.Experientia. 1984 Nov 15;40(11):1165-72. doi: 10.1007/BF01946641. Experientia. 1984. PMID: 6437857 Review.
-
Peculiarities of L: -DOPA treatment of Parkinson's disease.Amino Acids. 2005 Mar;28(2):157-64. doi: 10.1007/s00726-005-0162-4. Epub 2005 Mar 9. Amino Acids. 2005. PMID: 15750845 Review.
Cited by
-
Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.Naunyn Schmiedebergs Arch Pharmacol. 1983 Dec;324(4):271-4. doi: 10.1007/BF00502622. Naunyn Schmiedebergs Arch Pharmacol. 1983. PMID: 6686648
-
Chronic L-DOPA treatment of mice: a behavioural and biochemical study.J Neural Transm. 1981;50(2-4):209-24. doi: 10.1007/BF01249143. J Neural Transm. 1981. PMID: 6787171
-
Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.Psychopharmacology (Berl). 1985;85(3):333-9. doi: 10.1007/BF00428198. Psychopharmacology (Berl). 1985. PMID: 3923520
-
Differentiation of apomorphine from bromocriptine, piribidel and TRH by chronic administration in rats.Psychopharmacology (Berl). 1982;76(1):70-4. doi: 10.1007/BF00430759. Psychopharmacology (Berl). 1982. PMID: 6805012 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources